MSParis2017: Clinical Updates on Disease Modifying Therapies to Improve Outcomes for Patients with Multiple Sclerosis

This educational activity will feature content presented at the MS Paris 2017 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Four expert faculty will examine recent prognosis and diagnostic strategies of multiple sclerosis. An analysis of clinical trial data of current and emerging disease modifying therapies as presented at the Joint ACTRIMS-ECTRIMS meeting will be discussed. The faculty will also review how to implement recent scientific data to safely manage patients with multiple sclerosis for optimal outcomes. Upon completion of this activity, learners will gain a better understanding of recent clinical trial data for the treatment of multiple sclerosis, ultimately improving patient outcomes.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of neurologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with multiple sclerosis.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Identify recent prognosis and diagnostic strategies of multiple sclerosis.
  2. Review clinical trial data of current and emerging disease modifying therapies as presented at the Joint ACTRIMS-ECTRIMS meeting.
  3. Incorporate recent scientific data to safely manage patients with multiple sclerosis for optimal outcomes.

FACULTY

 
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY
 
Peter Calabresi, MD
Director, Division of Neuroimmunology
Professor of Neurology
The Johns Hopkins Hospital
Baltimore, MD
 
Stephen Krieger, MD
Assistant Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Director, Neurology Residency Program
Icahn School of Medicine at Mount Sinai
New York, NY
Michael Racke, MD
Professor of Neurology and Neuroscience
Wexler Medical Center at The Ohio State University Medical Center
Columbus, OH

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Fred D. Lublin, MD
Consultant/Advisor: AbbVie; Acorda; Pharmaceuticals Ltd; Akros; Atara Biotherapeutics; Bayer HealthCare Pharmaceuticals; Biogen; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Innate Immunotherapeutics; Mapi Pharma; MedDay; MedImmune; Novartis Pharmaceuticals Corporation; Polypharma; Receptos; Regeneron; F. Hoffmann-La Roche Ltd; Sanofi; Teva Neuroscience, Inc.; TG Therapeutics; Toyama
 
Grant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; NIH; NMSS; Novartis Pharmaceuticals Corporation; Sanofi; Teva Neuroscience, Inc.; Transparency Life Sciences
 
Speakers Bureau: Genentech, Inc.; Genzyme Corporation

Peter Calabresi, MD

Consultant/Advisor: Biogen; Disarm Therapeutics

Grant/Research Support: Annexon, Inc.; Genzyme Corporation; MedImmune

Stephen Krieger, MD

Consultant/Advisor: Acorda Therapeutics; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Mallinckrodt; Novartis Pharmaceuticals Corporation; TG Therapeutics, Inc.; Teva Pharmaceutical Industries Ltd.

Speakers Bureau: Biogen

Michael K. Racke, MD
Consultant/Advisor: Teva Neuroscience, Inc.
 
Grant/Research Support: Actelion Pharmaceuticals Ltd; Alkermes; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; TG Therapeutics, Inc.
 
Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Chelsey Benedek hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This CME activity has been supported by an independent educational grant from Sanofi Genzyme.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
01/12/2018
Course expires: 
01/11/2019
Rating: 
5

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
01/12/2018
Course expires: 
01/11/2019
Please login or register to take this course.